Is Parnax Lab overvalued or undervalued?

As of 10 November 2025, Parnax Lab's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company is currently considered undervalued, supported by a PE ratio of 13.34, an EV to EBITDA of 8.24, and a ROE of 13.86%. In comparison to its peers, Parnax Lab's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 359.8, and PTC India, which is classified as very attractive with a PE ratio of 7.89.
Despite recent stock performance showing a decline of 25.27% year-to-date compared to a 6.91% gain in the Sensex, Parnax Lab's strong financial ratios and improved valuation grade suggest that it may present a compelling investment opportunity. The company's solid fundamentals, including a PEG ratio of 2.54, further reinforce the notion that it is undervalued relative to its peers in the pharmaceuticals and biotechnology industry.